[Safety of lornoxicam in G-6-PDH deficiency].
OBJECTIVE
To assess the safety of lornoxicam in subjects with G-6-PDH deficiency.


METHODS
Open controlled 2-week in vivo study on lornoxicam 8 mg bid in subjects with G-6-PDH deficiency suffering from rheumatic diseases.


RESULTS
In 8 male patients with the Mediterranean form of G-6-PDH deficiency (mean age +/- SD, 54.3 years +/- 7.2) lornoxicam showed no influence on red blood cells (RBC) survival curve. The RBC half-life was the same before and after two weeks of treatment.


CONCLUSIONS
Lornoxicam caused no RBC damage and evidenced favourable safety in subjects with G-6-PDH deficiency, suffering from rheumatic diseases.
Perpignano
G
G
Cattedra di Reumatologia I, Università degli Studi di Cagliari, Italia.
Cacace
E
E
Matulli
C
C
Ruggiero
V
V
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D001168:Arthritis / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D004905:Erythrocyte Aging / Q000187:drug effects; D005955:Glucosephosphate Dehydrogenase Deficiency / Q000097:blood / Q000150:complications*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010894:Piroxicam / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology* / Q000627:therapeutic use; D013997:Time Factors
D000894:Anti-Inflammatory Agents, Non-Steroidal; D010894:Piroxicam; C059451:lornoxicam